Evidence map›Paper›PMID 36945054›Full record

ArticleJournal of experimental & clinical cancer research : CR2023

ALDOC- and ENO2- driven glucose metabolism sustains 3D tumor spheroids growth regardless of nutrient environmental conditions: a multi-omics analysis.

Claudia De Vitis, Anna Martina Battaglia, Matteo Pallocca, Gianluca Santamaria, Maria Chiara Mimmi, Alessandro Sacco, Francesca De Nicola, Marco Gaspari, Valentina Salvati, Francesca Ascenzi and 21 more

Open access · goldFull text read
In one paragraph

Article in Journal of experimental & clinical cancer research : CR, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
34citing papers in PubMed, 1 pooled it
14.4field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

34 citing papers in PubMed, 1 synthesis or guideline pooled it, 52 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Metabolic Reprogramming in Melanoma: An Epigenetic Point of View.Pharmaceuticals (Basel, Switzerland) · 2025
    Review
  16. Article
  17. Mass Spectrometry-Based Applications of Spheroids in Cancer Biology.Annual review of analytical chemistry (Palo Alto, Calif.) · 2025
    Review
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

31 authors at 8 institutions in 2 countries.

Claudia De Vitis *Department of Clinical and Molecular Medicine, Sant'Andrea Hospital, ''Sapienza'' University of Rome, Rome, Italy.
Anna Martina Battaglia *Department of Experimental and Clinical Medicine, ''Magna Graecia'' University of Catanzaro, Catanzaro, Italy.
Matteo PalloccaBiostatistics, Bioinformatics and Clinical Trial Center, IRCCS ''Regina Elena'' National Cancer Institute, Rome, Italy.
Gianluca SantamariaDepartment of Experimental and Clinical Medicine, ''Magna Graecia'' University of Catanzaro, Catanzaro, Italy.
Maria Chiara MimmiGenomic and Post-Genomic Unit, IRCCS Mondino Foundation, Pavia, Italy.
Alessandro SaccoDepartment of Experimental and Clinical Medicine, ''Magna Graecia'' University of Catanzaro, Catanzaro, Italy.
Francesca De NicolaSAFU Laboratory, IRCCS ''Regina Elena'' National Cancer Institute, Rome, Italy.
Marco GaspariDepartment of Experimental and Clinical Medicine, ''Magna Graecia'' University of Catanzaro, Catanzaro, Italy.
Valentina SalvatiPreclinical Models and New Therapeutic Agents Unit, IRCCS ''Regina Elena'' National Cancer Institute, Rome, Italy.
Francesca AscenziDepartment of Clinical and Molecular Medicine, Sant'Andrea Hospital, ''Sapienza'' University of Rome, Rome, Italy.
Sara BruschiniDepartment of Clinical and Molecular Medicine, Sant'Andrea Hospital, ''Sapienza'' University of Rome, Rome, Italy.
Antonella EspositoDepartment of Experimental and Clinical Medicine, ''Magna Graecia'' University of Catanzaro, Catanzaro, Italy.
Giulia RicciDepartment of Experimental Medicine, Università Degli Studi Della Campania ''Luigi Vanvitelli'', Naples, Italy.
Eleonora SperandioBiostatistics, Bioinformatics and Clinical Trial Center, IRCCS ''Regina Elena'' National Cancer Institute, Rome, Italy.
Alice MassacciBiostatistics, Bioinformatics and Clinical Trial Center, IRCCS ''Regina Elena'' National Cancer Institute, Rome, Italy.
Licia Elvira PrestagiacomoDepartment of Experimental and Clinical Medicine, ''Magna Graecia'' University of Catanzaro, Catanzaro, Italy.
Andrea VecchioneDepartment of Clinical and Molecular Medicine, Sant'Andrea Hospital, ''Sapienza'' University of Rome, Rome, Italy.
Alberto RicciRespiratory Unit, Sant'Andrea Hospital, Sapienza University of Rome, Rome, Italy.
Salvatore SciacchitanoDepartment of Clinical and Molecular Medicine, Sant'Andrea Hospital, ''Sapienza'' University of Rome, Rome, Italy.
Gerardo SalernoDepartment of Neurosciences, Mental Health and Sensory Organs (NESMOS), Sapienza University of Rome, Rome, Italy.
Deborah FrenchDepartment of Clinical and Molecular Medicine, Sant'Andrea Hospital, ''Sapienza'' University of Rome, Rome, Italy.
Ilenia AversaDepartment of Experimental and Clinical Medicine, ''Magna Graecia'' University of Catanzaro, Catanzaro, Italy.
Cristina CeredaGenomic and Post-Genomic Unit, IRCCS Mondino Foundation, Pavia, Italy.
Maurizio FanciulliSAFU Laboratory, IRCCS ''Regina Elena'' National Cancer Institute, Rome, Italy.
Ferdinando ChiaradonnaDepartment of Biotechnology and Biosciences, University of Milano-Bicocca, Milan, Italy.
Egle SolitoBarts and The London School of Medicine and Dentistry, William Harvey Research Institute, Queen Mary University of London, London, E1 2AT, UK.
Giovanni CudaDepartment of Experimental and Clinical Medicine, ''Magna Graecia'' University of Catanzaro, Catanzaro, Italy.
Francesco CostanzoDepartment of Experimental and Clinical Medicine, ''Magna Graecia'' University of Catanzaro, Catanzaro, Italy.
Gennaro CilibertoScientific Director, IRCCS ''Regina Elena'' National Cancer Institute, Rome, Italy.
Rita ManciniDepartment of Clinical and Molecular Medicine, Sant'Andrea Hospital, ''Sapienza'' University of Rome, Rome, Italy. rita.mancini@uniroma1.it.ORCID http://orcid.org/0000-0002-5491-2449
Flavia BiamonteDepartment of Experimental and Clinical Medicine, ''Magna Graecia'' University of Catanzaro, Catanzaro, Italy.
Magna Graecia University · ITSapienza University of Rome · ITIstituti di Ricovero e Cura a Carattere Scientifico · ITItalian institute for Genomic Medicine · ITQueen Mary University of London · GBAzienda Ospedaliera Sant'Andrea · ITUniversity of Campania "Luigi Vanvitelli" · ITUniversity of Milano-Bicocca · IT

Funding

Associazione italiana ricerca per il cancro (AIRC) IG24451Sapienza Università di Roma RP12117A7C149F70
6 · The paper itself

Abstract

backgroundMetastases are the major cause of cancer-related morbidity and mortality. By the time cancer cells detach from their primary site to eventually spread to distant sites, they need to acquire the ability to survive in non-adherent conditions and to proliferate within a new microenvironment in spite of stressing conditions that may severely constrain the metastatic process. In this study, we gained insight into the molecular mechanisms allowing cancer cells to survive and proliferate in an anchorage-independent manner, regardless of both tumor-intrinsic variables and nutrient culture conditions.

methods3D spheroids derived from lung adenocarcinoma (LUAD) and breast cancer cells were cultured in either nutrient-rich or -restricted culture conditions. A multi-omics approach, including transcriptomics, proteomics, and metabolomics, was used to explore the molecular changes underlying the transition from 2 to 3D cultures. Small interfering RNA-mediated loss of function assays were used to validate the role of the identified differentially expressed genes and proteins in H460 and HCC827 LUAD as well as in MCF7 and T47D breast cancer cell lines.

resultsWe found that the transition from 2 to 3D cultures of H460 and MCF7 cells is associated with significant changes in the expression of genes and proteins involved in metabolic reprogramming. In particular, we observed that 3D tumor spheroid growth implies the overexpression of ALDOC and ENO2 glycolytic enzymes concomitant with the enhanced consumption of glucose and fructose and the enhanced production of lactate. Transfection with siRNA against both ALDOC and ENO2 determined a significant reduction in lactate production, viability and size of 3D tumor spheroids produced by H460, HCC827, MCF7, and T47D cell lines.

conclusionsOur results show that anchorage-independent survival and growth of cancer cells are supported by changes in genes and proteins that drive glucose metabolism towards an enhanced lactate production. Notably, this finding is valid for all lung and breast cancer cell lines we have analyzed in different nutrient environmental conditions. broader Validation of this mechanism in other cancer cells of different origin will be necessary to broaden the role of ALDOC and ENO2 to other tumor types. Future in vivo studies will be necessary to assess the role of ALDOC and ENO2 in cancer metastasis.

Indexed as

Breast NeoplasmsMultiomicsCell Line, TumorCell ProliferationFemaleGlucoseHumansLactatesNutrientsPhosphopyruvate HydrataseSpheroids, CellularTumor MicroenvironmentENO2 protein, humanGlucoseLactatesNutrientsPhosphopyruvate HydrataseALDOCBreast cancerENO2Glucose metabolismLung cancerMetastasisOmicsTumor spheroids

Identifiers

PMID36945054
PMCPMC10031988
OpenAlexW4328052644

What OpenQuestion holds

Textfull text, public
LicenceCC BY
measurements read61
table measurements read20
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.